It's been a while since we covered Cordlife Group, the No.1 private cord blood banking group in Singapore. 

cryovial3.14A cryovial containing processed umbilical cord lining segments. Photo: CompanyCordlife has re-appeared on some investors' radar because it could become a really big player in Asia if a proposed merger with a Chinese peer materialises.

Cordlife on 4 June 2019 announced a proposal for a merger, via a share swap, with Global Cord Blood Corporation (GCBC).

Negotiations are still ongoing.

Some salient facts in the public domain about GCBC, foremost of which is that it shares the same Chinese controlling shareholder (Sanpower Group) as Cordlife:

• GCBC's current market cap is about US$690 million on the New York Stock Exchange. 

• It is the first and largest umbilical cord blood banking operator in China.

• It holds 3 out of 7 licences currently available in China, and has 750,000 subscribers as of March 2019.

• It had a market share of more than 44% in China, as of Dec 2017.


Here are 6 things to get up to speed about Cordlife:

1. Market presence: Cordlife has roughly a 70% market share in its home ground (Singapore) where it has been established for 18 years.

The 70% market share figure is anything but precise: It is based on Cordlife's "market intelligence".

In its 1H2019 presentation material, Cordlife said it is N0.1 not only in Singapore but also Hong Kong, Philippines, and Indonesia. 

It is No. 2 in Malaysia and No.3 in India. The Group is thus one of the leading providers for cord blood, cord lining and cord tissue banking services in the region.

2. More on market presence: In Singapore, the players (ie Cordlife, Cryoviva and Stemcord) have collectively a penetration rate of about 20% in private hospitals.  

TanPohLan arCEO Tan Poh Lan owns 205,440 shares of Cordlife. Photo: CompanyThat suggests there is room for growth as consumers become aware of Cordlife's services. The growth potential is even more stark in overseas markets.

3. Assets:
Apart from Singapore, Cordlife has processing and storage facilities in five other key markets -- Hong Kong, Malaysia, India, Indonesia and the Philippines. It also has brand presence in Myanmar and Vietnam.

The Group is one of the first private cord blood banks in Asia to release cord blood units for transplants and cellular therapy. To date, the Group has released more than 500 stem cell units for use in successful transplants and therapies.

Tan Poh Lan

Feb 2019 – present
(Cordlife Group)

Chief Executive Officer

April 2016 – Feb 2019 (Cordlife Group)

Group Chief Operating Officer

April 2016 - October 2016
(Cordlife Group)

Group Chief Operating Officer and Executive Director

2008 – 2011
 (Gleneagles Hospital)

Chief Executive Officer

  2011 - 2012
(Vinmec International Hospital, Hanoi)

Chief Executive Officer

(Fortis Healthcare Singapore)

Chief Executive Officer

4. New management: In March 2016, Jeremy Yee resigned as CEO after five years at the helm of Cordlife. 

Two successors came and went before Ms Tan Poh Lan, then the group chief operating officer, was appointed CEO in Feb 2019.

Notably, she has a track record of being CEO of top hospitals (see table).

ChooBoonYong819CFO Choo Boon Yong at 1H2019 results briefing. NextInsight photo.5. 1H2019 financial highlights: Cordlife reported $33.1 million in revenue for 1H2019, down 3.6% y-o-y, partly because baby deliveries were lower in Singapore, Hong Kong and Malaysia.

Accordingly, gross profit was S$22.0 mllion (-3.8% y-o-y).

The gross profit margin was an attractive 66.3%, which is a blend of  margins across the various markets and across businesses of cord blood banking, cord lining banking, cord tissue banking and diagnostic test services.

Selling and marketing expenses and administration expenses consumed a large part of the gross profit.

In 1H2019, these expenses were reined in, which helped net profit rise to S$1.4 million (+45.4% y-o-y).

Stock price 

46 c

52-week range

36 - 63 c

PE (ttm)


Market cap

S$117 m

Shares outstanding

253.7 m



1-year return


Source: Bloomberg

6. Valuation: Cordlife had S$42.7 million net cash as at end-June 2019 (+S$4.0 million from end-Dec 2018).

That's 37% of the current market cap of S$117 million (stock price: 46 cents). 

Net asset value was 46.6 cents a share, ie same as the recent stock price. 

The game changer would be a successful merger with GCBC, as it would be highly earnings-accretive.

Under a proposed share swap, GCBC shares would be converted into Cordlife shares and GCBC will be delisted from the New York Stock Exchange.

The merged entity (Cordlife listed on Singapore Exchange) would be the largest cord blood bank in the world.

Stay tuned.

The 1H2019 Powerpoint presentation material is here.

Share Prices

Counter NameLastChange
AEM Holdings1.180-0.010
Avi-Tech Electronics0.345-
Best World Int.1.360-
China Sunsine1.1000.010
CNMC GoldMine0.2850.005
CSE Global0.4700.005
Eagle HTrust USD0.6600.005
Food Empire0.500-0.005
Golden Energy0.170-0.003
GSS Energy0.069-
ISDN Holdings0.225-
JB Foods0.645-0.010
KSH Holdings0.4650.005
Moya Asia0.063-
Nordic Group0.265-
Oxley Holdings0.305-0.005
REX International0.0860.001
Sing Holdings0.390-
Straco Corp.0.755-
Sunningdale Tech1.230-
Sunpower Group0.4500.015
The Trendlines0.078-
Tiong Seng0.215-
Uni-Asia Group0.710-0.005
Yangzijiang Shipbldg1.010-0.040

NextInsight RSS

rss_2 NextInsight - Latest News

Online Now

We have 1293 guests and no members online